Longeveron Secures Chinese Patent for Stem Cell Potency Assay Methods

Longeveron Inc. (LGVN) announced that the China National Intellectual Property Administration (CNIPA) has granted the company a new patent covering its proprietary potency assay methods. These methods are used for assessing human mesenchymal stem cells (MSCs), which are central to the company's therapeutic development pipeline. This intellectual property milestone significantly strengthens Longeveron's position in the Chinese market, one of the world's largest healthcare sectors. The patented methodology allows for more precise evaluation of stem cell quality and effectiveness during the manufacturing process. By securing these rights, the company protects its core technological assets and enhances its potential for future licensing and strategic partnerships in the region. Market analysts view this development as a positive step for the biotech firm's global expansion strategy and long-term valuation.